

well as the risks of infection with reprocessed duodenoscopes. Subject matter of the panel meeting will include potential methods and expert assessment of how to reduce EtO emissions to the environment from medical device sterilization processes without compromising assurance of sterility or effective processing of medical devices. The panel will also discuss recommendations to reduce the risk of infection from reprocessed duodenoscopes.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be publicly available at the location of the advisory committee meeting and the background material will be posted on FDA's website after the meeting. Background material will be available at <https://www.fda.gov/advisory-committees/advisory-committee-calendar>. Scroll down to the appropriate advisory committee meeting link.

FDA plans to provide a live webcast of the November 6 and 7, 2019, meeting of the General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee. While CDRH is working to make webcasts available to the public for all advisory committee meetings, there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible. The link for the webcast is available at: <https://collaboration.fda.gov>. Webcast information, including the website address for the webcast, are the following, for their respective days:

November 6, 2019: <http://>

[fda.yorkcast.com/webcast/Play/eed34f9b1f448f9a1f6ad05a4b98d7d1d](http://fda.yorkcast.com/webcast/Play/eed34f9b1f448f9a1f6ad05a4b98d7d1d)

November 7, 2019: <http://>

[fda.yorkcast.com/webcast/Play/49c5a76d5d1c422d8da028441ab557de1d](http://fda.yorkcast.com/webcast/Play/49c5a76d5d1c422d8da028441ab557de1d)

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. Written submissions may be made to the contact person on or before October 22, 2019. Oral presentations from the public will be scheduled on November 6, 2019, between approximately 1:30 p.m. and 2 p.m. and from 3:50 p.m. to 4:20 p.m. and on November 7, 2019, between approximately 1:20 p.m. and 1:50 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief

statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before October 16, 2019. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by October 17, 2019.

Persons attending FDA's advisory committee meetings are advised that FDA is not responsible for providing access to electrical outlets.

For press inquiries, please contact the Office of Media Affairs at [fdaoma@fda.hhs.gov](mailto:fdaoma@fda.hhs.gov) or 301-796-4540.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Artair Mallett, at [Artair.Mallett@fda.hhs.gov](mailto:Artair.Mallett@fda.hhs.gov) or 301-796-9638 at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at <https://www.fda.gov/advisory-committees/about-advisory-committees/public-conduct-during-fda-advisory-committee-meetings>.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 29, 2019.

**Lowell J. Schiller,**

*Principal Associate Commissioner for Policy.*  
[FR Doc. 2019-19079 Filed 9-3-19; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Service Administration

#### Meeting of the Advisory Committee on Training in Primary Care and Dentistry

**AGENCY:** Health Resources and Service Administration (HRSA), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, this notice announces that the Advisory Committee on Training in Primary Care

and Dentistry (ACTPCMD) has scheduled a public meeting. Information about ACTPCMD and the agenda for this meeting can be found on the ACTPCMD website at: <https://www.hrsa.gov/advisory-committees/primarycare-dentist/index.html>.

**DATES:** October 31, 2019, 10:00 a.m.–5:00 p.m. Eastern Time.

**ADDRESSES:** This meeting will be held by webinar.

- **Webinar link:** <https://hrsa.connectsolutions.com/ACTPCMD>.

- **Conference Call in number:** (888) 455-0640; Passcode: HRSA COUNCIL (voice response).

**FOR FURTHER INFORMATION CONTACT:**

Kennita Carter, MD, Senior Advisor and Designated Federal Official, Division of Medicine and Dentistry, HRSA, 5600 Fishers Lane, Rockville, Maryland 20857; phone (301) 945-3505; or email [BHWACTPCMD@hrsa.gov](mailto:BHWACTPCMD@hrsa.gov).

**SUPPLEMENTARY INFORMATION:**

ACTPCMD provides advice and recommendations to the Secretary of HHS (Secretary) on policy, program development, and other matters of significance concerning the activities under section 747 of Title VII of the Public Health Service (PHS) Act, as it existed upon the enactment of Section 749 of the PHS Act in 1998.

At this meeting, ACTPCMD will discuss matters concerning innovations in training in primary care medicine and dentistry as well as ACTPCMD's upcoming report and recommendations. Agenda items are subject to change as priorities dictate. Refer to the ACTPCMD website for any updated information concerning the meeting. An agenda will be posted on the website at least 14 calendar days before the meeting. Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting. Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to ACTPCMD should be sent to Kennita Carter using the contact information above at least three business days prior to the meeting.

Individuals who plan to attend and need special assistance or another reasonable accommodation should notify Kennita Carter at the address and phone number listed above at least 10 business days before the meeting.

**Maria G. Button,**

*Director, Division of the Executive Secretariat.*  
[FR Doc. 2019-19035 Filed 9-3-19; 8:45 am]

**BILLING CODE 4165-15-P**